Corticosteroids for Eosinophilic Esophagitis in Children: A Meta-analysis

被引:9
作者
Munoz-Osores, Elizabeth [1 ]
Maldonado-Campos, Isabel [1 ]
Olivares-Labbe, Maria T. [4 ]
Villarroel, Luis [3 ]
Gana, Juan Cristobal [1 ,2 ]
机构
[1] Pontificia Univ Catolica Chile, Escuela Med, Div Pediat, Diagonal Paraguay 362,8 Piso, Santiago 8330077, Chile
[2] Pontificia Univ Catolica Chile, Escuela Med, Dept Gastroenterol & Nutr, Diagonal Paraguay 362,8 Piso, Santiago 8330077, Chile
[3] Pontificia Univ Catolica Chile, Fac Med, Dept Publ Hlth, Santiago, Chile
[4] Pontificia Univ Catolica Chile, UC Lib Syst SIBUC, Santiago, Chile
关键词
ORAL BUDESONIDE SUSPENSION; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; FLUTICASONE PROPIONATE; VISCOUS BUDESONIDE; PEDIATRIC SUBJECTS; TOPICAL STEROIDS; DIAGNOSIS; DYSPHAGIA; EFFICACY;
D O I
10.1542/peds.2020-0874
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
CONTEXT: Treatment of eosinophilic esophagitis (EoE) is focused on dietary, pharmacologic, and endoscopic therapy options. Within the pharmacologic alternatives, topical corticosteroids are the most used, and a large number of studies evaluating their effectiveness have been published, requiring a new summary of evidence. OBJECTIVE: To evaluate the histologic and clinical effectiveness of the use of corticosteroids in pediatric patients with a diagnosis of EoE. DATA SOURCES: Cochrane Central Register of Controlled Trials, Medline, Embase, Science Citation Index Expanded, Conference Proceedings Citation Index-Science, Latin American and Caribbean Health Sciences Literature, and (June 2019). STUDY SELECTION: We selected randomized controlled trials assessing corticosteroids versus a placebo or dietary treatment of EoE in children. DATA EXTRACTION: Methodologic quality of evidence was evaluated by using the Cochrane Collaboration's risk of bias tool and the Grading of Recommendations Assessment, Development, and Evaluation system. The primary outcomes were clinical and histologic improvement. RESULTS: A total of 1655 studies were identified. Five studies were included (206 patients). Histologic response was 49.25% in the corticosteroids group and 4.16% in the placebo group (risk ratio 11.05 [confidence interval 3.8-32.15]; P < .0001). Symptomatic response was 33.6% in the corticosteroids group and 21.8% in the control group (risk ratio 1.62 [confidence interval 0.94-2.79]; P = .08). There were no major adverse effects. LIMITATIONS: Heterogeneity of the diagnosis of EoE. CONCLUSIONS: Our review revealed favorable results of corticosteroids versus placebo, mainly in histologic response. More studies are needed, by using validated clinical scores, to obtain more reliable results.
引用
收藏
页数:16
相关论文
共 46 条
[1]   Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids [J].
Aceves, S. S. ;
Newbury, R. O. ;
Chen, D. ;
Mueller, J. ;
Dohil, R. ;
Hoffman, H. ;
Bastian, J. F. ;
Broide, D. H. .
ALLERGY, 2010, 65 (01) :109-116
[2]   Oral viscous budesonide: A potential new therapy for eosinophilic esophagitis in children [J].
Aceves, Seema S. ;
Bastian, John F. ;
Newbury, Robert O. ;
Dohil, Ranjan .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (10) :2271-2279
[3]   Pediatric Esophageal Disorders: Diagnosis and Treatment of Reflux and Eosinophilic Esophagitis [J].
Adamiak, Tonya ;
Plati, Karen Francolla .
PEDIATRICS IN REVIEW, 2018, 39 (08) :392-402
[4]   Swallowed Fluticasone Propionate Is an Effective Long-Term Maintenance Therapy for Children With Eosinophilic Esophagitis [J].
Andreae, Doerthe A. ;
Hanna, Matthew G. ;
Magid, Margret S. ;
Malerba, Stefano ;
Andreae, Michael H. ;
Bagiella, Emilia ;
Chehade, Mirna .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (08) :1187-1197
[5]   Efficacy, Dose Reduction, and Resistance to High-Dose Fluticasone in Patients With Eosinophilic Esophagitis [J].
Butz, Bridget K. ;
Wen, Ting ;
Gleich, Gerald J. ;
Furuta, Glenn T. ;
Spergel, Jonathan ;
King, Eileen ;
Kramer, Robert E. ;
Collins, Margaret H. ;
Stucke, Emily ;
Mangeot, Colleen ;
Jackson, W. Daniel ;
O'Gorman, Molly ;
Abonia, J. Pablo ;
Pentiuk, Scott ;
Putnam, Philip E. ;
Rothenberg, Marc E. .
GASTROENTEROLOGY, 2014, 147 (02) :324-+
[6]  
Collins MH, 2011, GASTROENTEROLOGY, V140, pS237
[7]   Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis [J].
Dellon, E. S. ;
Irani, A-M ;
Hill, M. R. ;
Hirano, I. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (06) :634-642
[8]   A Conceptual Approach to Understanding Treatment Response in Eosinophilic Esophagitis [J].
Dellon, Evan S. ;
Gupta, Sandeep K. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (11) :2149-2160
[9]   Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis [J].
Dellon, Evan S. ;
Katzka, David A. ;
Collins, Margaret H. ;
Gupta, Sandeep K. ;
Lan, Lan ;
Williams, James ;
Hirano, Ikuo .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (04) :666-+
[10]   Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis [J].
Dellon, Evan S. ;
Katzka, David A. ;
Collins, Margaret H. ;
Hamdani, Mohamed ;
Gupta, Sandeep K. ;
Hirano, Ikuo .
GASTROENTEROLOGY, 2017, 152 (04) :776-+